630
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists

ORCID Icon, , , , , , , , , , , , , , , & show all
Pages 387-398 | Received 31 May 2020, Accepted 29 Sep 2020, Published online: 11 Oct 2020

References

  • SEER cancer statistics factsheets: acute myeloid leukemia. Bethesda (MD): National Cancer Institute. http://seer.cancer.gov/statfacts/html/amyl.html.
  • Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090–1098.
  • Löwenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7(9):1268–1274.
  • Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677.
  • Tawfik B, Sliesoraitis S, Lyerly S, et al. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014;93(1):47–55.
  • Medeiros BC, Satram-Hoang S, Momin F, et al. Real-world treatment patterns and comparative effectiveness among a population of elderly patients with acute myeloid leukemia (AML). Blood. 2018;132(Supplement 1):835–835.
  • Bhatt VR, Shostrom V, Armitage JO, et al. Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia. Am J Hematol. 2019;94(6):E169–E172.
  • LeBlanc TW, Walter RB, Hernandez-Aldama L, et al. Treatment decision making in AML: factors of importance to clinicians, AML patients and their family. Blood. 2019;134(Supplement_1):3498–3498.
  • Richardson DR, Seo J, Smith BD, et al. Quantifying patient preferences for treatment outcomes in AML: a discrete-choice experiment. Blood. 2018;132(Supplement 1):718–718.
  • Tariman JD, Doorenbos A, Schepp KG, et al. Patient, physician and contextual factors are influential in the treatment decision making of older adults newly diagnosed with symptomatic myeloma. Cancer Treatment Communications. 2014;2(2–3):34–47.
  • van der Poel MW, Mulder WJ, Ossenkoppele GJ, et al. Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study. Ann Hematol. 2015;94(8):1373–1379.
  • Mohile SG, Magnuson A, Pandya C, et al. Community oncologists' decision-making for treatment of older patients with cancer. J Natl Compr Canc Netw. 2018;16(3):301–309.
  • George TI, Erba HP, Steensma DP, et al. Current diagnosis patterns for acute myeloid leukemia (AML) in clinical practice compared with World Health Organization (WHO) 2008 recommendations: outcomes from the CONNECT Myelodysplastic Syndromes (MDS) and AML Disease Registry. Blood. 2016;128(22):3548–3548.
  • Peditto K. Reporting qualitative research: standards, challenges, and implications for health design. Herd. 2018;11(2):16–19.
  • Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357.
  • Desch CE, Blayney DW. Making the choice between academic oncology and community practice: the Big Picture and Details About Each Career. J Oncol Pract. 2006;2(3):132–136.
  • Zafar SY, Alexander SC, Weinfurt KP, et al. Decision making and quality of life in the treatment of cancer: a review. Supp Care Cancer. 2009;17(2):117–127.
  • Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
  • Ando H, Cousins R, Young C. Achieving saturation in thematic analysis: development and refinement of a codebook. Compr Psychol. 2014;3:03.CP.3.4–04.
  • Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–1288.
  • Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18(4):809–816.
  • LeBlanc TW. Shared decision-making in acute myeloid leukemia. Semin Oncol Nurs. 2019;35(6):150958
  • Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018;131(5):515–524.
  • Klepin HD, Estey E, Kadia T. More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate. Am Soc Clin Oncol Educ Book. 2019;39:421–432.
  • Loh KP, Klepin HD. Geriatric assessment in older patients with acute myeloid leukemia. Cancers. 2018;10(7):225.
  • Molga A, Wall M, Chhetri R, et al. Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. J Geriatr Oncol. 2020;11(1):114–120.
  • Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287–4294.
  • Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98(2):208–216.
  • Mohile SG, Epstein RM, Hurria A, et al. Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program. JAMA Oncol. 2019;6(2):1–9.
  • Mohile SG, Velarde C, Hurria A, et al. Geriatric assessment-guided care processes for older adults: a delphi consensus of geriatric oncology experts. J Natl Compr Canc Netw. 2015;13(9):1120–1130.
  • Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–3465.
  • Hurria A, Akiba C, Kim J, et al. Reliability, validity, and feasibility of a computer-based geriatric assessment for older adults with cancer. JOP. 2016;12(12):e1025–e1034.
  • Nathwani N, Kurtin SE, Lipe B, et al. Integrating touchscreen-based geriatric assessment and frailty screening for adults with multiple myeloma to drive personalized treatment decisions. J Oncol Pract. 2019;16(1):e92–e99.
  • Bergkvist K, Larsen J, Johansson UB, Mattsson J, et al. Hospital care or home care after allogeneic hematopoietic stem cell transplantation-patients' experiences of care and support. Eur J Oncol Nurs. 2013;17(4):389–395.
  • Shahrokni A, Maggiore RJ, Ghassemzadeh H. New technologies in geriatric oncology care. J Geriatr Oncol. 2018;9(6):687–689.
  • Bolle S, Smets EMA, Hamaker ME, et al. Medical decision making for older patients during multidisciplinary oncology team meetings. J Geriatr Oncol. 2019;10(1):74–83.
  • de Angst IB, Kil PJM, Bangma CH, et al. Should we involve patients more actively? Perspectives of the multidisciplinary team on shared decision-making for older patients with metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2019;10(4):653–658.
  • Shea CM, Teal R, Haynes-Maslow L, et al. Assessing the feasibility of a virtual tumor board program: a case study. J Healthc Manag. 2014;59(3):177–193.
  • Lesslie M, Parikh JR. Implementing a multidisciplinary tumor board in the community practice setting. Diagnostics. 2017;7(4):55.
  • Jansen J, Butow PN, van Weert JC, et al. Does age really matter? Recall of information presented to newly referred patients with cancer. J Clin Oncol. 2008;26(33):5450–5457.
  • van Weert JC, Jansen J, Spreeuwenberg PM, et al. Effects of communication skills training and a Question Prompt Sheet to improve communication with older cancer patients: a randomized controlled trial. Crit Rev Oncol Hematol. 2011;80(1):145–159.
  • McCarthy DM, Waite KR, Curtis LM, et al. What did the doctor say? Health literacy and recall of medical instructions. Med Care. 2012;50:277–282.
  • Elwyn G, Durand MA, Song J, et al. A three-talk model for shared decision making: multistage consultation process. Bmj. 2017;359:j4891.
  • Schnitzler L, Smith SK, Shepherd HL, et al. Communication during radiation therapy education sessions: the role of medical jargon and emotional support in clarifying patient confusion. Patient Educ Couns. 2017;100(1):112–120.
  • Mandelblatt JS, Edge SB, Meropol NJ, et al. Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J Clin Oncol. 2003;21(5):855–863.
  • Gattellari M, Butow PN, Tattersall MH. Sharing decisions in cancer care. Soc Sci Med. 2001;52(12):1865–1878.
  • Lai C, Doucette K, Norsworthy K. Recent drug approvals for acute myeloid leukemia. J Hematol Oncol. 2019;12(1):100.
  • Abdallah M, Xie Z, Ready A, et al. Management of acute myeloid leukemia (AML) in older patients. Curr Oncol Rep. 2020;22(10):103.
  • Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis Good Research Practices Task Force. Value Health. 2016;19(4):300–315.
  • Wilson L, Loucks A, Bui C, et al. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci. 2014;344(1–2):80–87.
  • Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
  • DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
  • Glatzer M, Panje CM, Siren C, et al. Treatment options in oncology. Oncology. 2018;2:1–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.